Loading...
  • CDK4 or CDK6
  • This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activtiy is required for cell cycle G1/S transition. (genetex.com)
  • This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. (genetex.com)
  • hematopoietic
  • In early stages, the CDK6 kinase induces a complex transcriptional program to block p53 in hematopoietic cells. (aacrjournals.org)
  • We here show that cyclin‐dependent kinase 6 (Cdk6) is specifically expressed in proliferating hematopoietic progenitor cells, and that Cdk6 inhibits transcriptional activation by Runx1, but not C/EBPα or PU.1. (embopress.org)
  • Since Runx transcription factors play central roles in hematopoietic, neuronal and osteogenic lineages, this novel, noncanonical Cdk6 function may control terminal differentiation in multiple tissues and cell types. (embopress.org)
  • detection
  • Western blot analysis of whole cell lysates probed with cdk6 antibody ( VMA00022 ) followed by detection with HRP conjugated Goat anti Mouse IgG (1/10,000, STAR207P ) and visualized on the ChemiDoc MP with 106 second exposure. (bio-rad-antibodies.com)
  • The data is compared side-by-side and if the antibody is specific there will be no detection in the knockout sample or cell line but specific detection in the normal cell line. (labbulletin.com)
  • The detection antibody was a Goat anti-Rabbit IgG Antibody Peroxidase conjugate. (abcam.com)
  • proliferation
  • End points were cdk6/cyclin D 1 expression and human β-cell proliferation, survival, and function. (diabetesjournals.org)
  • Increasing doses of Dox led to marked dose- and time-related increases in cdk6 and cyclin D 1 , accompanied by a 20-fold increase in β-cell proliferation. (diabetesjournals.org)
  • Notably, Dox withdrawal resulted in a reversal of both cdk6 and cyclin D 1 expression as well as β-cell proliferation. (diabetesjournals.org)
  • We found that ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes. (biomedcentral.com)
  • miR-494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma. (abcam.com)
  • CDK6(Cyclin-dependent kinase 6) is involved in initiation and maintenance of cell cycle exit during cell differentiation and it prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types.The range of the molecular weight is 34-50 KDa (PMID: 23563707, 17420273, 8114739). (ptglab.com)
  • Using the OP9-DL1 system to deliver temporally controlled Notch receptor-dependent signaling, we show that CDK6 is required for Notch-dependent survival, proliferation, and differentiation. (aacrjournals.org)
  • Cdk6 expression increased myeloid progenitor proliferation, and inhibited myeloid lineage‐specific gene expression and terminal differentiation in vitro and in vivo . (embopress.org)
  • It was also observed that restored CDK6 expression in the miR‑25 mimic‑treated VSMCs partly reduced miR‑25‑mediated VSMC proliferation. (spandidos-publications.com)
  • In the current study, it was hypothesized that the expression of miR-25 was inhibited in TNF-α-stimulated VSMCs and that overexpression of miR-25 in the VSMCs inhibited cell proliferation by targeting cyclin-dependent kinase 6 (CDK6). (spandidos-publications.com)
  • Human
  • Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies. (lsbio.com)
  • Mouse anti Human cdk6 antibody recognizes cdk6 as a single band of ~37 kDa in multiple cell line lysates by western blotting under reducing conditions. (bio-rad-antibodies.com)
  • We have shown that it is possible to drive adult human β-cells to replicate robustly, using in vitro and in vivo models, by delivery of cell cycle molecules such as cyclin-dependent kinase 6 (cdk6) and cyclin D 1 ( 8 - 11 ). (diabetesjournals.org)
  • The findings are relevant to human patients: Tumors with low levels of CDK6 have mutations in TP53 significantly more often than expected. (aacrjournals.org)
  • Cyclin-dependent kinase 6 (CDK6) promotes cell cycle progression and is overexpressed in human lymphoid malignancies. (aacrjournals.org)
  • These results show a critical requirement for CDK6 in Notch/Akt-dependent T-cell development and tumorigenesis and strongly support CDK6 as a specific therapeutic target in human lymphoid malignancies. (aacrjournals.org)
  • These products are affinity-purified IgG antibodies that recognize human cyclin D1. (clontech.com)
  • IHC-P analysis of human stomach tissue using GTX32545 Cyclin D2 antibody. (genetex.com)
  • RUNX1
  • WB Suggested Anti-RUNX1 Antibody Titration: 0.2-1 ug/ml. (acris-antibodies.com)
  • Cdk6 inhibits Runx1 activity by binding to the runt domain of Runx1, interfering with Runx1 DNA binding and Runx1‐C/EBPα interaction. (embopress.org)
  • Cdk6‐mediated inhibition of granulocytic differentiation could be reversed by excess Runx1, consistent with Runx1 being the major target for Cdk6. (embopress.org)
  • species
  • Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. (abcam.com)
  • overexpression
  • It can be accomplished by introduction of cell cycle molecules such as cyclin-dependent kinase 6 (cdk6) and cyclin D 1 , but their continuous overexpression raises oncogenic concerns. (diabetesjournals.org)
  • A drawback of these studies is that they were performed using continuous overexpression of cdk6 and cyclin D 1 driven by the constitutive cytomegalovirus (CMV) promoter in adenoviral vectors, raising concerns of oncogenic transformation over the long term. (diabetesjournals.org)
  • therapeutic
  • Get access to the best antibodies, discovery platforms, and know-how to advance your diagnostic and therapeutic programs. (abcam.com)
  • Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery. (abcam.com)
  • regulates
  • CDK6 is a multifunctional protein that negatively regulates both pRB and p27 KIP1 (p27) activity ( 7 ) and modulates differentiation of certain cells ( 8 ). (aacrjournals.org)